Alpha Cognition Aktie
Marktkapitalisierung
104,08 Mio. $
104,08 Mio. $
Streubesitz
36,01%
KGV
-6,99
Index-Zuordnung
-
Alpha Cognition Inc Unternehmensprofil
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The companys commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimers disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimers disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Vorstand
Herr Michael E. McFadden B.B.A.
CEO & Direktor
Herr Kenneth Anthony Cawkell B.A., LL.B.
Gründer, Berater, Unternehmenssekretär & Direktor
Herr Henry H. Du CPA
VP of Finance & Buchhaltung und Interim-CFO
Frau Lauren D'Angelo M.B.A.
Operativer Geschäftsführer
Dr. Denis G. Kay M.Sc., Ph.D.
Wissenschaftlicher Leiter
Herr Timothy Ayers
Leiter der Abteilung Compliance
Frau Christine Enthüllung
Vizepräsident für Marketing & Kommerzielle Strategie
Aktionärsstruktur
55,649%
Freefloat
53,548%
Institutionelle Aktionäre
2,101%
Individuelle Aktionäre
Termine
Stammdaten
| Nennwert/Aktie | - |
| Land | USA |
| Währung | USD |
| Branche | Biotechnologie |
| Aktientyp | - |
| Sektor | Gesundheit |
| Gattung | - |
Quelle: Leeway